274 related articles for article (PubMed ID: 9498700)
1. The role of MDR-1 in refractory lymphoma.
Sandor V; Wilson W; Fojo T; Bates SE
Leuk Lymphoma; 1997 Dec; 28(1-2):23-31. PubMed ID: 9498700
[TBL] [Abstract][Full Text] [Related]
2. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
3. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
4. Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay.
Zhan Z; Sandor VA; Gamelin E; Regis J; Dickstein B; Wilson W; Fojo AT; Bates SE
Blood; 1997 May; 89(10):3795-800. PubMed ID: 9160686
[TBL] [Abstract][Full Text] [Related]
5. Visualization of multidrug resistance in vivo.
Hendrikse NH; Franssen EJ; van der Graaf WT; Vaalburg W; de Vries EG
Eur J Nucl Med; 1999 Mar; 26(3):283-93. PubMed ID: 10079321
[TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer.
Lehne G
Curr Drug Targets; 2000 Jul; 1(1):85-99. PubMed ID: 11475537
[TBL] [Abstract][Full Text] [Related]
7. Reversing antibiotic resistance.
Hodgkinson R; Sharples D
Expert Opin Investig Drugs; 2002 Aug; 11(8):1023-32. PubMed ID: 12150699
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of action of P-glycoprotein in relation to passive membrane permeation.
Eytan GD; Kuchel PW
Int Rev Cytol; 1999; 190():175-250. PubMed ID: 10331240
[TBL] [Abstract][Full Text] [Related]
9. Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlation with P glycoprotein expression and activity in vivo.
Brinkmann U
Novartis Found Symp; 2002; 243():207-10; discussion 210-2, 231-5. PubMed ID: 11990778
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of multidrug resistance in cancer chemotherapy.
Nooter K; Stoter G
Pathol Res Pract; 1996 Jul; 192(7):768-80. PubMed ID: 8880878
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.
Pallis M; Turzanski J; Higashi Y; Russell N
Leuk Lymphoma; 2002 Jun; 43(6):1221-8. PubMed ID: 12152989
[TBL] [Abstract][Full Text] [Related]
12. MDR1/P-glycoprotein expression in colorectal cancer.
Linn SC; Giaccone G
Eur J Cancer; 1995; 31A(7-8):1291-4. PubMed ID: 7577038
[TBL] [Abstract][Full Text] [Related]
13. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
14. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators.
Krishna R; Mayer LD
Curr Med Chem Anticancer Agents; 2001 Aug; 1(2):163-74. PubMed ID: 12678765
[TBL] [Abstract][Full Text] [Related]
15. Expression of the multidrug transporter P-glycoprotein is inversely related to that of apoptosis-associated endogenous TRAIL.
Souza PS; Madigan JP; Gillet JP; Kapoor K; Ambudkar SV; Maia RC; Gottesman MM; Fung KL
Exp Cell Res; 2015 Aug; 336(2):318-28. PubMed ID: 26101157
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention.
Kaye SB
Curr Opin Oncol; 1998 Aug; 10 Suppl 1():S15-9. PubMed ID: 9801854
[TBL] [Abstract][Full Text] [Related]
17. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance.
Moore AS; Leveille CR; Reimann KA; Shu H; Arias IM
Cancer Invest; 1995; 13(5):475-9. PubMed ID: 7552813
[TBL] [Abstract][Full Text] [Related]
18. Classical multidrug resistance in acute myeloid leukaemia.
Paietta E
Med Oncol; 1997 Mar; 14(1):53-60. PubMed ID: 9232613
[TBL] [Abstract][Full Text] [Related]
19. Multidrug resistance through the spectacle of P-glycoprotein.
Goda K; Bacsó Z; Szabó G
Curr Cancer Drug Targets; 2009 May; 9(3):281-97. PubMed ID: 19442049
[TBL] [Abstract][Full Text] [Related]
20. The medicinal chemistry of multidrug resistance (MDR) reversing drugs.
Teodori E; Dei S; Scapecchi S; Gualtieri F
Farmaco; 2002 May; 57(5):385-415. PubMed ID: 12058813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
